TTPH - Tetraphase Pharma Summary, Stock Quote and News

2.320 0 (0%)

Data as of Oct 22, 2018

Prev. Close 2.32
Price Open
Volume 0
Day's Range -
52 Wk Range 2.05 - 6.97
50 Day Moving Avg. 2.94
PE Ratio 0
Shares Outstanding 52.86M
Market Cap 122.63M

Trade TTPH stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
9/06/18	WBB Securities	Upgrades	Speculative BuyBuy	0.0
8/28/18	B. Riley FBR	Maintains	BuyBuy	7.0
8/28/18	H.C. Wainwright	Maintains	BuyBuy	7.0

20 Stocks Moving In Friday's Pre-Market Session Lisa LevinFri, 12 Oct 2018 08:20:31 -0400
A Peek Into The Markets: US Stock Futures Gain Ahead Of Citigroup, Wells Fargo Earnings Lisa LevinFri, 12 Oct 2018 07:49:21 -0400
Tetraphase Pharmaceuticals shares are trading higher after the company announced the commercial launch of its Intra-Abdominal Infection treatment, XERAVA, in the US. luke@benzinga.comFri, 12 Oct 2018 07:40:52 -0400
The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program Shanthi RexalineFri, 12 Oct 2018 07:34:03 -0400
6 Stocks To Watch For October 12, 2018 Lisa LevinFri, 12 Oct 2018 04:45:43 -0400
Tetraphase shares are trading up 13% after the company announced the commercial launch of its Intra-Abdominal Infection treatment, XERAVA, in the US. Benzinga_NewsdeskThu, 11 Oct 2018 16:53:00 -0400
5 Stocks Moving In Thursday's After-Hours Session Brett HershmanThu, 11 Oct 2018 16:46:09 -0400
Tetraphase Pharmaceuticals Announces Commercial Launch Of XERAVA In United States Benzinga_NewsdeskThu, 11 Oct 2018 16:01:36 -0400
Tetraphase Pharmaceuticals shares are up 12.8% premarket after the company announced the presentation of Phase 3 XERAVA data at IDWeek 2018; XERAVA demonstrated efficacy in treating secondary bacteramia in patients. Benzinga NewsdeskMon, 08 Oct 2018 08:24:45 -0400
32 Stocks Moving In Monday's Pre-Market Session Lisa LevinMon, 08 Oct 2018 08:03:28 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Consolidated Research: 2018 Summary Expectations for Vuzix, BCE, Tetraphase Pharmaceuticals, T2 Biosystems, TPG Specialty Lending, and Jianpu Technology — Fundamental Analysis, Key Performance Indications Globe Newswire49 min ago
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States Globe NewswireOct 11, 2018
Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018 Globe NewswireOct 08, 2018
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe NewswireSep 28, 2018
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business WireSep 25, 2018
Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference Globe NewswireSep 24, 2018
CLASS ACTION UPDATE for RMTI, TTPH, HMNY and GDS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders Globe NewswireSep 23, 2018
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZN, RMTI, TTPH, HMNY, PM and QRTEA Globe NewswireSep 21, 2018
DEADLINE ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. (TTPH) and Lead Plaintiff Deadline – September 25, 2018 Globe NewswireSep 21, 2018
SHAREHOLDER ALERT: ZN RMTI TTPH ABBV HMNY GDS PVG OPK USAT TRCO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines Globe NewswireSep 20, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Premarket Gainers as of 9:05 am (10/12/2018) Seeking AlphaOct 12, 2018
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States GuruFocusOct 11, 2018
After Hours Gainers / Losers (10/11/2018) Seeking AlphaOct 11, 2018
Tetraphase launches eravacycline in U.S.; shares up 13% after hours Seeking AlphaOct 11, 2018
Tetraphase Pharmaceuticals announces positive data from clinical trials of XERAVA and TP-6076 at IDWeek 2018 Seeking AlphaOct 08, 2018
Tetraphase: A Strong Player In The Antibiotic Resistance Field Seeking AlphaOct 04, 2018
Options Traders Expect Huge Moves in Tetraphase (TTPH) Stock ZacksOct 04, 2018
Antibiotic developers in the green on Paratek news Seeking AlphaOct 03, 2018
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 56'5(c)(4) GuruFocusSep 28, 2018
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZN, RMTI, ... GuruFocusSep 21, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2018	EST	Actual	Surprise
EPS:	-0.37	-0.18	0.19
Rev:	2.19M	11.58M	9.39M

Q3 2018	EST	Actual	Surprise
EPS:	Expected 2018-11-01
Rev:	Expected 2018-11-01

Company Profile

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners